ThermoGenesis (THMO) Stock Price, News & Analysis

Company Overview

ThermoGenesis Holdings, Inc. (NASDAQ: THMO) is a biotechnology company focused on the development and commercialization of automated cell processing systems for clinical and laboratory applications. The company’s core technologies enable the separation, concentration and washing of blood components and cellular products, supporting transfusion medicine, regenerative therapies and cell-based research. ThermoGenesis’s platforms are designed to streamline workflow, reduce manual intervention and maintain high levels of sterility and recovery for a range of cell types.

Key product lines include automated systems for platelet-rich plasma (PRP) preparation, hematopoietic stem cell processing and blood component separation. ThermoGenesis’s instruments and single‐use disposables are marketed under brand names such as Sepax™ for stem cell isolation, Magellan® for PRP concentration and Cellution® for advanced cell therapy workflows. These solutions are used by hospitals, blood centers, cord blood banks and research institutions across North America, Europe and select markets in Asia Pacific.

Founded in California, ThermoGenesis is headquartered in Rancho Cordova and maintains a global distribution network to support its instrument installations and consumable supply. The company operates under rigorous regulatory standards, including U.S. Food and Drug Administration (FDA) clearances and CE marking for its systems. ThermoGenesis’s management team brings experience in medical device development, clinical manufacturing and global commercialization, with a strategic focus on advancing personalized and regenerative medicine through automated cell processing innovations.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 29 shs
• Average Volume: 4,517 shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

THMO Stock Analysis - Frequently Asked Questions

How were ThermoGenesis' earnings last quarter?

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) announced its quarterly earnings data on Friday, November, 12th. The company reported ($6.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.60) by $3.15. The business earned $3.16 million during the quarter, compared to analyst estimates of $3.06 million.

When did ThermoGenesis' stock split?

ThermoGenesis's stock reverse split before market open on Friday, December 23rd 2022.The 1-45 reverse split was announced on Friday, December 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ThermoGenesis?

Shares of THMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ThermoGenesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ThermoGenesis investors own include FuelCell Energy (FCEL), Teladoc Health (TDOC), Zoom Communications (ZM), Bionano Genomics (BNGO), Co-Diagnostics (CODX), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Laboratory apparatus & furniture
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:THMO
• CIK: 811212
• Web: www.thermogenesis.com
• Phone: (916) 858-5100
• Fax: 916-858-5199
• Employees: 40
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $9.61 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.99) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,953,000
• Free Float: 1,750,000
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: 1.18